(Q34560089)

English

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

scientific article

In more languages
default for all languages
No label defined

No description defined

Statements

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. (English)
EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group
Australasian Gastrointestinal Trials Group

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit